New Survey of Drug Industry Professionals Finds Strong Support for Cloning of Human Cells Life Scientists & Industry Executives Express Skepticism of Nanotechnology's

Benefits



    WESTBOROUGH, Mass., Aug. 4 /PRNewswire/ -- Three quarters of bench
 scientists, industry leaders and pharmaceutical executives believe the United
 States should allow the cloning of human cells, according to a new survey
 released today by IBC Life Sciences. The survey measured industry views on
 current trends and issues in drug discovery and technology.
     Of the 468 drug discovery professionals surveyed, 72 percent said that the
 United States should pass legislation allowing the cloning of human cells to
 make embryonic stem cells for use in research. Only 13 percent disagreed, and
 15 percent said they were undecided on the topic of cloning.
     The stem cell results were just one of several intriguing findings of the
 IBC Life Sciences Survey, which was conducted last month in advance of 10th
 Annual IBC Life Sciences' Drug Discovery Technology(R) & Development World
 Congress, August 8-11, 2005 in Boston, Massachusetts.
     "Numerous public opinion polls have been conducted on drug discovery
 topics, but very few surveys have measured the views of the professionals
 working in the industry's labs and boardrooms," said Ellen Massa, marketing
 director at IBC Life Sciences.
     "Our survey found that industry professionals are skeptical of the hype
 surrounding nanotechnology-enabled drug delivery systems, for example. In
 fact, many scientists and industry leaders identified protein therapeutics as
 having the best growth potential in the next few years. A significant
 percentage said they are expecting a decrease in the costs associated with
 drug development," Massa added.
 
     Highlights of some of the survey findings include:
     * Some analysts believe nanotechnology-enabled drug delivery systems will
       generate revenues of more than $1.7 billion in 2009 and more than $4.8
       billion in 2012. But, according to the IBC Life Sciences, 66 percent
       believe those revenue predictions are overstated. Thirty-one percent
       said analysts are on target and three percent described expert
       expectations are too pessimistic.
     * More than one-third of those surveyed (34 percent) chose protein
       therapeutics as the category of drugs that will experience the highest
       growth in the next five years, followed by small molecules (27 percent)
       and antibody therapeutics (25 percent). Only nine percent indicated
       that vaccines would foresee the highest growth.
     * Currently, the average drug development process takes 15 years and costs
       between $800 million and $1.7 billion.  Approximately 40 percent of the
       industry scientists and professionals surveyed expect these costs will
       decrease. More than one-third (33 percent) said they expect drug
       development costs will increase over the next five years.
 
     Survey respondents also answered questions regarding barriers in drug
 research and development; the FDA's new Critical Path Initiative; and,
 technologies that have significantly impacted drug research or development and
 companies' shift from drug discovery to drug development.  A complete list of
 questions and survey results is available at http://www.drugdisc.com/survey.
     In addition to conducting this survey on drug discovery and technology,
 IBC Life Sciences' Drug Discovery Technology(R) & Development World Congress
 will address several topics on the recent trends in drug discovery. FDA
 Commissioner, Dr. Lester Crawford will be the keynote speaker and additional
 sessions will be led by key industry leaders such as, Dr. John L. LaMattina,
 President of Pfizer Global Research and Development and Dr. Robert R. Ruffolo,
 Jr., President of research and development at Wyeth Pharmaceuticals.
 
     About 10th Anniversary Drug Discovery Technology(R) & Development World
 Congress
     The Drug Discovery Technology(R) & Development World Congress is designed
 for drug discovery researchers and business executives to evaluate and
 understand the latest scientific, business and informatics advances in drug
 discovery research. In addition to a full conference program of speakers and
 keynotes, this event features an exhibit hall of 350+ exhibit booths
 showcasing the newest technologies and products that are driving the drug
 discovery field. Drug Discovery Technology(R) & Development 2005 will be held
 August 8-11, 2005 at Boston Convention & Exhibition Center in Boston, MA.  For
 conference details, visit http://www.drugdisc.com/us.
     Free exhibit hall and keynote passes are available through Friday, August
 5 at http://www.drugdisc.com/pass.
 
     About IBC Life Sciences
     IBC Life Sciences is an independent organizer that is in business to
 provide an unbiased forum for the evaluation of current research, market
 trends, technological developments and applications. IBC Life Sciences is part
 of IBC USA Conferences, Inc., part of The Informa Group plc (London: INF). The
 Informa Group has been a publisher and event organizer in the life sciences
 industry for over 20 years. IBC USA Conferences is headquartered in
 Westborough, Massachusetts.
 
     Information
     For questions contact:
      IBC USA Conferences
      Ellen Massa
      Senior Marketing Manager
      Telephone: (508) 616-5550 Ext. 213
      E-mail: emassa@ibcusa.com
      http://www.drugdisc.com
 
 

SOURCE IBC Life Sciences

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.